Table 2. Crude and adjusted hazard ratios for factors associated with retention in the Cervical Cancer Screening Cascade.
Univariable analyses | Multivariable analysis | |||||
---|---|---|---|---|---|---|
n = 1251 | n = 1251 | |||||
HR | 95% CI | P value | HR | 95% CI | P value | |
Age, years | ||||||
18–25 | 2.02 | 1.61–2.54 | 1.40 | 1.07–1.82 | ||
25–44 | 1 | - | <0.001 | 1 | - | 0.025 |
>45 | 2.19 | 1.71–2.80 | 1.50 | 1.12–2.03 | ||
Relationship | ||||||
Single | 0.78 | 0.67–0.90 | 0.83 | 0.71–0.98 | ||
Relationship | 1 | - | 0.002 | 1 | - | 0.076 |
Separated | 0.98 | 0.85–1.14 | 0.92 | 0.78–1.08 | ||
Employment | ||||||
Unemployed | 1 | - | 1 | - | ||
Employed | 0.98 | 0.86–1.12 | <0.001 | 0.93 | 0.81–1.06 | 0.388 |
Student | 0.45 | 0.29–0.70 | 0.81 | 0.51–1.30 | ||
Parity | ||||||
0 | 1 | - | 1 | - | ||
1 to 3 | 1.77 | 1.44–2.19 | <0.001 | 1.46 | 1.15–1.86 | 0.008 |
>3 | 1.37 | 1.08–1.73 | 1.41 | 1.07–1.85 | ||
HIV RNA viral load at VIA screening, copies/mm 3 | ||||||
<50 | 1 | - | 1 | - | ||
50–1000 | 1.21 | 0.99–1.47 | <0.001 | 1.19 | 0.96–1.47 | <0.001 |
>1000 | 1.36 | 1.19–1.55 | 1.33 | 1.16–1.53 | ||
Calendar period enrolled | ||||||
Early years: 2012–2014 | 1 | - | 1 | - | ||
Later years: 2015–2017 | 1.31 | 1.16–1.49 | <0.001 | 1.26 | 1.10–1.43 | <0.001 |
Nadir CD4 cell count, cells/mm3 | ||||||
<200 | 1 | - | ||||
200–349 | 1.02 | 0.86–1.29 | ||||
350–500 | 1.40 | 1.86–1.26 | 0.977 | |||
>500 | 1.02 | 0.84–1.24 | ||||
HIV RNA viral load at ART enrollment, copies/mm 3 | ||||||
<50 | 1 | - | ||||
50–1000 | 0.79 | 0.62–1.01 | 0.150 | |||
>1000 | 0.96 | 0.84–1.10 |
Retention in the Cervical Cancer Screening Cascade is defined as all women living with HIV (WLHIV) achieving rescreening in either arm (screening or preventative treatment) of the Secondary Cervical Cancer Prevention Cascade. HR: hazards ratio; n: number of women; CI: confidence interval; HIV: human immunodeficiency virus; RNA: Ribonucleic acid; VIA: visual inspection with acetic acid; n: number of WLHIV.